Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Authors
Peters, SDafni, U
Boyer, M
De, R
Faivre-Finn, Corinne
Felip, E
Garrido, P
Girard, N
Guckenberger, M
Haanen, J
Le, P
Mornex, F
Ozsahin, M
Paz-Ares, L
Planchard, D
Raben, D
Ramalingam, S
Reck, M
Smit, E
Stahel, R
Stenzinger, A
Swanton, C
Vallone, S
Garassino, M
Affiliation
Oncology Department, Lausanne University and CHUV, SwitzerlandIssue Date
2019
Metadata
Show full item recordCitation
Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, et al. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Ann Oncol. 2019 Jan 8.Journal
Annals of OncologyDOI
10.1093/annonc/mdy553PubMed ID
30624547Additional Links
https://dx.doi.org/10.1093/annonc/mdy553Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy553
Scopus Count
Collections
Related articles
- A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer.
- Authors: Gill HS, Ramalingam SS
- Issue date: 2019 Jul 1
- Durvalumab boosts progression-free survival in NSCLC.
- Authors: Gourd E
- Issue date: 2018 Jan
- Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer.
- Authors: Shaverdian N, Offin MD, Rimner A, Shepherd AF, Wu AJ, Rudin CM, Hellmann MD, Chaft JE, Gomez DR
- Issue date: 2020 Mar
- Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
- Authors: Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ
- Issue date: 2019 Dec
- Atezolizumab (Tecentriq) for bladder cancer and NSCLC.
- Issue date: 2017 Feb 27